Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model
Rintaro Ono,
Takashi Watanabe,
Eiryo Kawakami,
Makoto Iwasaki,
Mariko Tomizawa-Murasawa,
Masashi Matsuda,
Yuho Najima,
Shinsuke Takagi,
Saera Fujiki,
Rumi Sato,
Yoshiki Mochizuki,
Hisahiro Yoshida,
Kaoru Sato,
Hiromasa Yabe,
Shunichi Kato,
Yoriko Saito,
Shuichi Taniguchi,
Leonard D. Shultz,
Osamu Ohara,
Masayuki Amagai,
Haruhiko Koseki,
Fumihiko Ishikawa
Affiliations
Rintaro Ono
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Takashi Watanabe
Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Eiryo Kawakami
Disease Biology Group, RIKEN Medical Sciences Innovation Hub Program (MIH), Yokohama 230-0045, Japan
Makoto Iwasaki
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Mariko Tomizawa-Murasawa
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Masashi Matsuda
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Yuho Najima
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Shinsuke Takagi
Department of Haematology, Toranomon Hospital, Tokyo 105-8470, Japan
Saera Fujiki
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Rumi Sato
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Yoshiki Mochizuki
Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Hisahiro Yoshida
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Kaoru Sato
Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan
Hiromasa Yabe
Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan
Shunichi Kato
Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan
Yoriko Saito
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Shuichi Taniguchi
Department of Haematology, Toranomon Hospital, Tokyo 105-8470, Japan
Leonard D. Shultz
The Jackson Laboratory, Bar Harbor 04609, ME, United States
Osamu Ohara
Laboratory for Integrative Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan; Department of Human Genome Research, Kazusa DNA Research Institute, Kisarazu 292-0818, Japan
Masayuki Amagai
Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan; Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan
Haruhiko Koseki
Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
Fumihiko Ishikawa
Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan; Corresponding author at: 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Background: Graft-versus host disease (GVHD) is a complication of stem cell transplantation associated with significant morbidity and mortality. Non-specific immune-suppression, the mainstay of treatment, may result in immune-surveillance dysfunction and disease recurrence. Methods: We created humanised mice model for chronic GVHD (cGVHD) by injecting cord blood (CB)-derived human CD34+CD38−CD45RA− haematopoietic stem/progenitor cells (HSPCs) into hIL-6 transgenic NOD/SCID/Il2rgKO (NSG) newborns, and compared GVHD progression with NSG newborns receiving CB CD34− cells mimicking acute GVHD. We characterised human immune cell subsets, target organ infiltration, T-cell repertoire (TCR) and transcriptome in the humanised mice. Findings: In cGVHD humanised mice, we found activation of T cells in the spleen, lung, liver, and skin, activation of macrophages in lung and liver, and loss of appendages in skin, obstruction of bronchioles in lung and portal fibrosis in liver recapitulating cGVHD. Acute GVHD humanised mice showed activation of T cells with skewed TCR repertoire without significant macrophage activation. Interpretation: Using humanised mouse models, we demonstrated distinct immune mechanisms contributing acute and chronic GVHD. In cGVHD model, co-activation of human HSPC-derived macrophages and T cells educated in the recipient thymus contributed to delayed onset, multi-organ disease. In acute GVHD model, mature human T cells contained in the graft resulted in rapid disease progression. These humanised mouse models may facilitate future development of new molecular medicine targeting GVHD. Keywords: Acute GVHD, Chronic GVHD, IL-6, Humanised mouse